Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Oxidoreductase
Patent
1999-03-18
2000-11-14
Nashed, Nashaat T.
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Oxidoreductase
4352523, 43525233, 4353201, 536 231, 536 232, 536 234, 536 237, C12N 902, C12N 120, C12N 1574, C07H 2104
Patent
active
061468630
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, the invention relates to polynucleotides and polypeptides of the 3-hydroxyacyl-CoA dehydrogenase family, as well as their variants, hereinafter referred to as "hcd," "hcd polynucleotide(s)," and "hcd polypeptide(s)" as the case may be.
BACKGROUND OF THE INVENTION
It is particularly preferred to employ staphylococcal genes and gene products as targets for the development of antibiotics. The staphylococci make up a medically important genera of microbes. They are known to produce two types of disease, invasive and toxigenic. Invasive infections are characterized generally by abscess formation effecting both skin surfaces and deep tissues. Staphylococcus aureus is the second leading cause of bacteremia in cancer patients. Osteomyelitis, septic arthritis, septic thrombophlebitis and acute bacterial endocarditis are also relatively common. There are at least three clinical conditions resulting from the toxigenic properties of staphylococci. The manifestation of these diseases result from the actions of exotoxins as opposed to tissue invasion and bacteremia. These conditions include: staphylococcal food poisoning, scalded skin syndrome and toxic shock syndrome.
The frequency of Staphylococcus aureus infections has risen dramatically in the past few decades. This has been attributed to the emergence of multiply antibiotic resistant stains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate Staphylococcus aureus strains which are resistant to some or all of the standard antibiotics. This phenomenon has created an unmet medical need and demand for new anti-microbial agents, vaccines, drug screening methods, and diagnostic tests for this organism.
Moreover, the drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics," that is, high throughput genome- or gene-based biology. This approach is rapidly superseding earlier approaches based on "positional cloning" and other methods. Functional genomics relies heavily on the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available as well as from other sources. There is a continuing and significant need to identify and characterize further genes and other polynucleotides sequences and their related polypeptides, as targets for drug discovery.
Clearly, there exists a need for polynucleotides and polypeptides, such as the hcd embodiments of the invention, that have a present benefit of, among other things, being useful to screen compounds for antimicrobial activity. Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists to find ways to prevent, ameliorate or correct such infection, dysfunction and disease.
3-Hydroxyacyl-coenzyme A dehydrogenase is part of the pathway for beta-oxidation of fatty acids. The enzyme acts in a multienzyme complex catalysing the oxidation of 3-hydroxyacyl coenzyme A to 3-oxoacyl coenzyme A (e.g. Clark D. P. & Cronan, J. E. 1996. Two carbon compounds and fatty acids as carbon sources, in Escherichia coli and Salmonella: Cellular and Molecular Biology, Neidhart F. C. (Ed) pp. 343-357, ASM Press). The related enzyme, 3-hydroxybutyryl-coenzyme A dehydrogenase, in the gram-positive anaerobic bacteria Clostridia are involved in the butyrate/butanol-producing pathway (e.g. Boynton Z L, Bennet G N, Rudolph F B 1996. Cloning, sequencing, and expression of clustered genes encoding beta-hydroxybutyryl-coenzyme A (CoA) ehydrogenase, crotonase, and butyryl-CoA dehydrogenase from Clostridium acetobutylicum ATCC 824. Journal of Bacteriology 178:3015-3024). The discovery of a Staphylococcus aureus gene enc
REFERENCES:
Boynton, et al., "Clostridium actobutylicum crotonase (crt), putative butyryl-CoA dehydrogenase (BCD), putative a-subunit of electron-transfer flavoprotein (etfA), putative b-subunit of electron-transfer flavoprotein (etfB), and 3-hydroxybutyryl-CoA dehydrogenase (hbd) genes, complete cds.", GenBank Submission, Accession No. U17110, Nov. 13, 1995.
Kunst, et al., "Bacillus subtilis complete genome (section 17 of 21): from 3197001 to 3414420.", GenBank Submission, Accession No. Z99120, Nov. 20, 1997.
Pancholi, et al., "A Major Surface Protein on Group A Streptocci Is a Glyceraldehyde-3 Phosphate-Dehydrogenase with Multiple Binding Activity", J. Exp. Med., vol. 176, pp. 415-426, published by The Rockefeller University Press, Aug., 1992.
Beattie David T
Deresiewicz Robert L
Hodgson John E
Lonetto Michael A
Lowe Adrian M
Deibert Thomas S.
Gimmi Edward R.
King William T.
Nashed Nashaat T.
SmithKline Beecham Corporation
LandOfFree
Staphylococcus aureus 3-hydroxyacyl-CoA dehydrogenase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Staphylococcus aureus 3-hydroxyacyl-CoA dehydrogenase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Staphylococcus aureus 3-hydroxyacyl-CoA dehydrogenase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2063869